Literature DB >> 27118127

Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer.

Amir Sabet1, Ina Binse2, Hong Grafe2, Samer Ezziddin3, Rainer Görges2, Thorsten D Poeppel2, Andreas Bockisch2, Sandra J Rosenbaum-Krumme2.   

Abstract

PURPOSE: Nodal involvement is an independent risk factor of recurrence in papillary thyroid cancer (PTC). Neither the international guidelines nor the recently introduced ongoing risk adaptation concept consider the extent of initial surgical clearance of radioiodine sensitive lymph node metastases in their stratification systems. We investigated the prognostic relevance of incomplete initial surgical clearance in patients with purely lymphogeneous metastatic PTC (pN1 M0) despite successful radioiodine therapy. Accurate assessment of pre-ablative nodal status was attempted using PET/CT studies with both (124)I-NaI and (18)F-FDG along with high-resolution cervical ultrasound.
METHODS: Sixty-five patients with histologically diagnosed lymph node metastases (pN1 M0) were retrospectively analyzed. Patients with iodine-negative lymph node metastases diagnosed by (18)F-FDG PET/CT or distant metastases were excluded from the analysis. The association of disease recurrence with the pre-ablative nodal status, as well as other baseline characteristics, were examined applying nonparametric tests for independent samples and multiple regression analysis. Patients with persistent lymph node metastases in (124)I-NaI PET/CT were further divided according to the additional presence or absence of FDG-uptake in (18)F-FDG PET/CT. Survival analyses were performed using Kaplan-Meier curves and the Cox proportional hazards model for uni- and multivariate analyses to assess the influence of prognostic factors on progression free survival (PFS).
RESULTS: Incomplete metastatic lymph node resection captured by (124)I-NaI PET/CT (n = 33) was an independent risk factor for recurrence (61 % vs 25 %, p = 0.006) and shorter PFS (46 months vs not reached, HR 4.0 [95 %-CI, 1.7-9.2], p = 0.001). Ultrasound could detect lymph node metastases only in 19/33 patients (58 %). Among patients with positive nodal status, FDG-avidity of metastatic iodine positive lymph nodes worsened the outcome (16 vs 69 months, p = 0.047). From all other investigated factors including age, N-stage (N1a vs N1b), and T-Stage (T4 vs T1-3), only large tumor size (pT4) had a significant impact on PFS (HR 2.9 [95 %-CI, 1.3-6.4], p = 0.007).
CONCLUSIONS: Incomplete initial surgical clearance of lymph node metastases even after successful radioiodine therapy may increase the chances of recurrence and is an independent risk factor for impaired survival of patients with PTC. Pre-ablative (dual tracer PET/CT) imaging with (124)I-Na and (18)F provides a prognostic tool for these patients and may considerably complement the current risk stratification systems.

Entities:  

Keywords:  Lymph node; PTC; Radioiodine therapy; Risk factor; Surgical clearance

Mesh:

Substances:

Year:  2016        PMID: 27118127     DOI: 10.1007/s00259-016-3400-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  42 in total

Review 1.  Postoperative management of differentiated thyroid cancer.

Authors:  Amin Sabet; Matthew Kim
Journal:  Otolaryngol Clin North Am       Date:  2010-04       Impact factor: 3.346

2.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.

Authors:  R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha
Journal:  Thyroid       Date:  2010-10-29       Impact factor: 6.568

Review 3.  Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Authors:  F Pacini; M G Castagna; L Brilli; G Pentheroudakis
Journal:  Ann Oncol       Date:  2009-05       Impact factor: 32.976

4.  Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study.

Authors:  Catharina Ihre Lundgren; Per Hall; Paul W Dickman; Jan Zedenius
Journal:  Cancer       Date:  2006-02-01       Impact factor: 6.860

Review 5.  Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.

Authors:  Lutz S Freudenberg; Walter Jentzen; Alexander Stahl; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

6.  Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer.

Authors:  Limin Yang; Weidong Shen; Naoko Sakamoto
Journal:  J Clin Oncol       Date:  2012-12-26       Impact factor: 44.544

7.  ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.

Authors:  Sandra J Rosenbaum-Krumme; Rainer Görges; Andreas Bockisch; Ina Binse
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06-21       Impact factor: 9.236

8.  Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer.

Authors:  W Wang; S M Larson; M Fazzari; S K Tickoo; K Kolbert; G Sgouros; H Yeung; H Macapinlac; J Rosai; R J Robbins
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

Review 9.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

10.  Response to initial therapy of differentiated thyroid cancer predicts the long-term outcome better than classical risk stratification systems.

Authors:  Albert Cano-Palomares; Ignasi Castells; Ismael Capel; Maria Rosa Bella; Santi Barcons; Angel Serrano; Xavier Guirao; Mercedes Rigla
Journal:  Int J Endocrinol       Date:  2014-07-08       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.